Olmesartan modulates proliferating cell nuclear antigen expression and improves dextran sulfate - induced ulcerative colitis in rats
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20210550Keywords:
UC, Olmesartan, Dextran sulfate TNF-α, MPO, PCNAAbstract
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by sudden attacks of remissions and exacerbations with increased incidence of cancer colon. The present study aims to determine the possible ameliorative mechanisms of Olmesartan in UC induced experimentally in rat.
Methods: Adult albino rats were randomly grouped into control, UC model non treated group: Rats received dextran sodium (DSS) orally for 21 days with intra-colic administration of acetic acid (AA) for 3 consecutive days for induction of UC model, Olmesartan (1, 5, 10mg/kg/orally) and UC + Olmesartan in different doses (1 mg, 5 mg and 10 mg/kg/day orally).
Results: DSS orally and AA intra-rectal produced sever colitis manifested by significant weight loss, watery and bloody diarrhea. Significant increase in serum and colonic tissue levels of tumor necrosis factor alpha and interleukine-1β. Pro-apoptotic Bax protein, myeloperoxidase (MPO) and expression of PCNA significantly increased in colonic tissue. Lipid peroxidation (MDA) significantly elevated while reduced glutathione (GSH) was depleted in UC non-treated group compared with normal control group. Treatment with Olmesartan (5 mg, 10 mg/kg/day, orally) ameliorated mucosal ulceration and improved inflammatory signs as confirmed by immunohistochemical and histopathological examination. Also, Olmesartan significantly attenuates overexpression of PCNA in colonic mucosa.
Conclusions: Our results point out that Olmesartan had ameliorative effects on UC by its anti-inflammatory, antioxidant and anti-apoptotic effects and attenuates PCNA expression which is the main cause of dysplasia and colorectal cancer. Olmesartan may be a promising therapeutic drug for treating UC and protection of colorectal carcinoma.
References
Zeng Z, Zhu Z, Yang Y, Ruan W, Peng X. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol. 2013;28(7):1148-53.
Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2(3):541-6.
Hartmann RM, Martins MI, Tieppo J, Fillmann HS, Marroni NP. Effect of Boswellia serrata on antioxidant status in an experimental model of colitis rats induced by acetic acid. Dig Dis Sci. 2012;57(8):2038-44.
Boussenna A, Cholet J, Goncalves-Mendes N, Joubert-Zakeyh J, Fraisse D. Polyphenol-rich grape pomace extracts protect against dextran sulfate sodium-induced colitis in rats. J Sci Food Agric. 2016; 96(4):1260-8.
Hozumi H, Hokari R, Kurihara C, Narimatsu K, Sato H, Sato S, et al. Endoscopic finding of spontaneous hemorrhage correlates with tumor necrosis factor alpha expression in colonic mucosa of patients with ulcerative colitis. Int J Colorectal Dis. 2013;28(8):1049-55.
Matuszyk A, Ceranowicz P, Warzecha Z, Cieszkowski J, Ceranowicz D, Gałązka K, et al. Exogenous Ghrelin Accelerates the Healing of Acetic Acid-Induced Colitis in Rats. Int J Mol Sci. 2016;17(9):1455.
Guerra GCB, Menezes MSSD, Araújo AAD, Júnior RFDA, Medeiros CACXD. Olmesartan Prevented Intra-articular Inflammation Induced by Zymosan in Rats. Biol Pharm Bull. 2016;39(11):1793-801.
Sun AN, Ren GY, Deng C, Zhang JJ, Luo XP, Wu XJ, et al. C-glycosyl flavonoid orientin improves chemically induced inflammatory bowel disease in mice. J Funct Foods. 2016;21:418-30.
Araújo AAD, Varela H, Brito GADC, Medeiros CACXD, Araújo LDS, Nascimento JHOD, et al. Azilsartan increases levels of IL-10, down-regulate MMP-2, MMP-9, RANKL/RANK, Cathepsin K and up-regulates OPG in an experimental periodontitis model. PLoS One. 2014;9:6750.
David E Mire 1, Tonous N Silfani, Michael K Pugsley. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005 Nov; 46(5):585-93.
Aurigena Antunes Araújo 1, Graziene Lopes de Souza, Tatiana Oliveira Souza, Gerly Anne de Castro Brito, Karoline Sabóia Aragão, Caroline Addison Xavier de Medeiros, Yriu Lourenço, Maria do Socorro Costa Feitosa Alves, Raimundo Fernandes de Araújo Jr. Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis. Naunyn Schmiedebergs Arch Pharmacol. 2013 Oct; 386(10):875-84.
Lei Zhu, PeiQing GU, Hong Shen. Protective Effects of Berberine Hydrochloride on DSS-induced Ulcerative Colitis in Rats. Int immunopharmacology. 2019;68:242-251.
Puneet Kaur Randhawa 1, Kavinder Singh 1, Nirmal Singh 1, Amteshwar Singh Jaggi 1. A review on chemical-induced inflammatory bowel disease models in rodents. Korean J Physiol Pharmacol 2014;18(4):279-88.
R.F. de Araújo Júnior, M.P.O. da Silva Reinaldo, G.A. de Castro Brito, P. de França Cavalcanti, M.A. de Moura Freire, C.A.X. de Medeiros, A.A. de Araújo. Olmesartan decreased levels of IL-1β and TNF-α, down-regulated MMP-2, MMP-9, COX-2, RANK/RANKL and up-regulated SOCs-1 in an intestinal mucositis model. PLoS One, 2014: e114923.
Weaker FJ, Richardson L: A modified processing and sectioning technique for hard tissues. Am J Med Technol. 1978;44(10):1030-2.
Noori, S.; Nasir, K and Mahboob, T. Effect of cocoa powder on oxidant /antioxidant in liver, heart and kidney tissue of rats The J Animal Plant Sci. 2020;4:174-8.
Noffsinger AE, Belli JM, Fogt F, Fischer J, Goldman H, Fenoglio-Preiser CM.A. germline hMSH2 alteration is unrelated to colonic microsatellite instability in patients with ulcerative colitis. Hum Pathol. 1999;30(1):8-12.
Wang YN, Li J, Zheng WY, Wu D, Yang H, Li Y, Lv H, Tan B, Shu HJ, Sun XY, Qian JM, Wu B, Li JN. Clinical characteristics of ulcerative colitis-related colorectal cancer in Chinese patients. J Dig Dis. 2017; 18(12):684-690.
Yang M, Lin HB, Gong S, Chen PY, Geng LL, Zeng YM, Li DY..Effect of Astragalus polysaccharides on expression of TNF-α, IL-1β and NFATc4 in a rat model of experimental colitis. Cytokine. 2014 Dec; 70(2):81-6.
Marchesi C, Paradis P, Schiffrin EL. Role of the renin‐angiotensinsystem in vascular inflammation. Trends Pharmacol Sci. 2008;29(7):367‐374.
Y. Waseda, M. Yasui, Y. Nishizawa, K. Inuzuka, H. Takato, Y. Ichikawa, A. Tagami, M. Fujimura, S. Nakao: Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice. Resp. Res. 2008;9:43.
S. David, P. Kümpers, A. Lukasz, J.T. Kielstein, H. Haller, D. Fliser: Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. J. Hypertens. 2009;27:1641-1647.
M.M. Nagib, M.G. Tadros, M.I. ELSayed, A.E. Khalifa. Anti-inflammatory and anti-oxidant activities of olmesartan medoxomil ameliorate experimental colitis in rats. Toxicol. Appl. Pharmacol., 271 (2013), pp. 106-113
T. Yamada, A. Kuno, K. Ogawa, M. Tang, K. Masuda, S. Nakamura, T. Ando, T. Okamoto, H. Ohara, T. Nomura. Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. J. Pharmacol. Exp. Ther., 313 (2005), pp. 36-45
Saber S, Khalil RM, Abdo WS, Nassif D, El-Ahwany E. Olmesartan ameliorates chemically-induced ulcerative colitis in rats via modulating NFκB and Nrf-2/HO-1 signaling crosstalk Toxicol Appl Pharmacol. 2019 Feb 1; 364:120-132.
Sohachi Fujimoto 1, Minoru Satoh, Hideyuki Horike, Hidekazu Hatta, Yoshisuke Haruna, Shinya Kobayashi, Tamehachi Namikoshi, Sayaka Arakawa, Naruya Tomita, Naoki Kashihara Olmesartan ameliorates progressive glomerular injury in subtotal nephrectomized rats through suppression of superoxide production. Hypertens Res 2008; 31(2):305-13.
Takahashi T, Konta T, Takasaki S, Ichikawa K, Takeishi Y, Kubota I. An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy. Clin Exp Nephrol. 2007;11(3):202-8.
M. Tsuda, M. Iwai, J.-M. Li, H.-S. Li, L.-J. Min, A. Ide, M. Okumura, J. Suzuki, M. Mogi, H. Suzuki. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension. 2005;45:545-51.
Zhijian Pan 1, Ling Feng 2, Haocheng Long 3, Hui Wang 1, Jiarui Feng 3, Feixiang Chen Effects of Local Pancreatic Renin-Angiotensin System on the Microcirculation of Rat with Severe Acute Pancreatitis. Korean J Physiol Pharmacol. 2015;19(4):299-30.
S.E. Andaloussi, I. Mäger, X.O. Breakefield, and M.J. Wood: Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov., 12 (2013), p. 347 View Record in Scopus.
M Shinozaki 1, T Watanabe, Y Kubota, T Sawada, H Nagawa, T Muto. High proliferative activity is associated with dysplasia in ulcerative colitis. Dis Colon Rectum. 2000;43(10 Suppl): S34-9.
Xuan Wang, Ya-Zhi Fan, Liang Yao, Jian-Ming Wang.: Anti-proliferative effect of olmesartan on Tenon's capsule fibroblasts. Int J Ophthalmo 2016; 9(5):669-76.
T Aizawa, N Ishizaka, K Kurokawa, R Nagai, H Nakajima, J Taguchi, M Ohno. Different effects of angiotensin II and catecholamine on renal cell apoptosis and proliferation in rats Kidney Int 2001;59(2):645-53.
